First Patient Dosed in Ph 1 Combo Cohort of MEM-288 + Docetaxel in Advanced NSCLC
“Dosing the first patient in this combination cohort marks an important milestone for the MEM-288 program,” said Mark Cantwell, Ph.D., Chief Scientific Officer, Memgen. “Docetaxel remains a backbone in the second-line setting, yet outcomes are still disappointing, with median overall survival typically less than one year. Combining intratumoral MEM-288 with chemotherapy has strong biological rationale. Our goal with this study is to improve the depth and durability of response and, ultimately, deliver a clinically meaningful improvement over the current standard of care for patients facing significant unmet need.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines